Atrial Natriuretic Peptide (ANP), rat: Benchmark Vasodilator Peptide for Cardiovascular Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino acid peptide hormone produced by atrial myocytes in response to cardiac stimuli, with a molecular weight of 1225.38 and a molecular formula of C₄₉H₈₄N₂₀O₁₅S (APExBIO). ANP acts as a potent vasodilator, reduces blood pressure, and regulates sodium, water, and adipose homeostasis [See also: advanced applications]. High-purity ANP (≥95.92% by HPLC/MS) from APExBIO is widely adopted in cardiovascular, renal, and metabolic studies. Clinical and preclinical research confirms ANP’s utility in dissecting natriuresis and vasodilation pathways (Zhang et al., 2022). Solutions should be freshly prepared and stored at -20°C, as the peptide is labile in aqueous solution (product page).

Biological Rationale

Atrial Natriuretic Peptide (ANP) is synthesized, stored, and secreted by atrial myocytes in the heart. Its secretion is triggered by physiological stimuli including atrial distension, angiotensin II, endothelin, and sympathetic nervous system activation (APExBIO). ANP circulates in plasma and functions as an endocrine hormone. It plays a crucial role in maintaining body fluid, sodium, potassium, and adipose tissue homeostasis. ANP is evolutionarily conserved and essential for cardiovascular health. Genetic knockout models demonstrate that loss of ANP signaling leads to salt-sensitive hypertension and impaired natriuresis (mechanistic review).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP exerts its biological effects by binding to natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylyl cyclase. Upon ligand binding, NPR-A converts GTP to cyclic GMP (cGMP). Elevated cGMP activates protein kinase G (PKG), leading to vasodilation and increased glomerular filtration rate. ANP suppresses renin and aldosterone secretion, resulting in natriuresis and diuresis. It also inhibits sympathetic nervous system activity and regulates adipocyte lipolysis. The rat ANP sequence is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH (APExBIO). The molecular mechanism is distinct from other natriuretic peptides due to its higher affinity for NPR-A and pronounced effects on sodium excretion (workflow contrast).

Evidence & Benchmarks

• ANP administration in rodents induces a rapid and sustained decrease in mean arterial blood pressure at doses ≥10 μg/kg, measured by tail-cuff plethysmography (Zhang et al., 2022, DOI:10.21203/rs.3.rs-2117207/v1).
• ANP increases urinary sodium excretion (natriuresis) by 30–50% within 2 hours post-injection at physiological pH 7.4 (APExBIO, product page).
• In vitro, ANP enhances cGMP levels in isolated rat cardiomyocytes by >2-fold within 30 minutes of exposure at 1 μM (protocols summary).
• Peptide purity for APExBIO’s product is validated at 95.92% by HPLC and mass spectrometry, exceeding typical research-grade standards (APExBIO).
• ANP solution is stable in DMSO (≥122.5 mg/mL) and water (≥43.5 mg/mL) but insoluble in ethanol, requiring careful solvent selection for reproducible results (APExBIO, product documentation).

Applications, Limits & Misconceptions

ANP (rat) is extensively used in cardiovascular, renal, and adipose tissue metabolism research. Its primary applications include:

• Modeling acute and chronic blood pressure regulation.
• Dissecting mechanisms of natriuresis and diuresis in renal physiology.
• Studying the interplay between cardiovascular homeostasis and adipose tissue metabolism.
• Screening pharmacological or genetic modulators of NPR-A/cGMP signaling.

This article extends recent reviews by offering updated solubility, purity, and workflow integration details not covered in advanced applications overviews.

Common Pitfalls or Misconceptions

• ANP (rat) does not cross-react with human NPR-A at identical potency; species-specific validation is required.
• Long-term storage of ANP solutions at 4°C leads to peptide degradation; only freshly prepared solutions are recommended.
• ANP is ineffective as a direct anti-inflammatory agent in models without functional NPR-A expression.
• The peptide is insoluble in ethanol; attempts to dissolve in alcohol yield precipitation and loss of activity.
• ANP’s effects on adipose tissue metabolism are secondary to its renal actions and may be blunted in hypovolemic states.

Workflow Integration & Parameters

For reproducible results, ANP (rat) from APExBIO should be handled and administered under defined conditions. Dissolve at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in sterile water. Avoid ethanol as a solvent. Prepare aliquots under sterile conditions and store at -20°C. Use immediately after thawing; avoid repeated freeze-thaw cycles. Recommended in vivo dosing ranges from 1–50 μg/kg, delivered intravenously or intraperitoneally, with physiological endpoints measured within 2 hours. In vitro, effective concentrations range from 10 nM to 1 μM for cGMP signaling assays. For detailed protocols and troubleshooting, refer to experimental best practices, which this article updates by including latest purity data and solvent compatibilities.

APExBIO’s Atrial Natriuretic Peptide (ANP), rat (SKU A1009) is supplied as a solid and should be stored at -20°C for long-term stability. All experimental procedures should be performed in accordance with institutional guidelines for animal research and peptide handling. For comprehensive scenario-based guidance, consult data-driven workflow solutions, which this article clarifies by focusing on solubility and stability constraints.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat, remains a cornerstone reagent for cardiovascular and renal physiology research due to its well-characterized mechanism, robust in vivo and in vitro efficacy, and high purity when sourced from APExBIO. Its application facilitates mechanistic studies of blood pressure homeostasis, natriuresis, and adipose tissue metabolism. Strict adherence to recommended storage, solvent, and dosing parameters is essential for reproducibility. Ongoing research will advance the clinical translation of ANP signaling pathways for hypertension, heart failure, and metabolic disorders (Zhang et al., 2022). For product specifications and ordering, see the Atrial Natriuretic Peptide (ANP), rat product page.